Associate Researcher, at Sun Yat-sen University Cancer, China📖
Dr. Jingjing Miao is an accomplished medical researcher and associate investigator at Sun Yat-sen University Cancer Center. With a robust educational foundation and extensive experience in nasopharyngeal carcinoma research, she has become a prominent figure in oncology, particularly in understanding radioresistance and advancing biomarker-based treatments. Recognized internationally for her contributions, she continues to lead research initiatives aimed at improving cancer care and patient outcomes.
Scopus Profile
Education Background🎓
Dr. Jingjing Miao holds a Ph.D. in Medicine from Sun Yat-sen University (2021), where she conducted research under the supervision of Prof. Xiang Guo. She completed her Master of Medicine at the same institution in 2017, guided by Prof. Chong Zhao, following her undergraduate medical training (M.B.B.S.) at the Second Clinical Medical College, Southern Medical University (2009–2014).
Dr. Miao is currently an Associate Researcher, Master’s Supervisor, and practicing physician in the Department of Nasopharyngeal Carcinoma at Sun Yat-sen University Cancer Center (2023–present). Previously, she served as a Postdoctoral Assistant Researcher in the same department (2021–2023), where her work significantly contributed to advancing precision medicine in oncology. Her expertise lies in nasopharyngeal carcinoma, with a focus on radioresistance and biomarker identification. Dr. Miao has also held key roles in professional committees, including serving as Deputy Secretary-General of the Nasopharyngeal Cancer Integrated Rehabilitation Committee of the Chinese Anti-Cancer Association.
Research Interests🔬
Dr. Miao specializes in nasopharyngeal carcinoma with an emphasis on the molecular mechanisms of radioresistance, biomarker discovery, and immuno-radiotherapy. She is dedicated to exploring the roles of RNA-binding proteins, long non-coding RNAs (lncRNAs), and stress granules in cancer treatment resistance, particularly in reirradiation scenarios.
Author Metrics
Dr. Miao has authored numerous high-impact research articles and conference presentations. Her work has garnered recognition through multiple awards, including ASCO Merit Awards (2019, 2021) and the prestigious “35 under 35” Outstanding Young Oncologists in China (2023). She has contributed significantly to journals and conferences, advancing the field of oncology through innovative approaches to treatment.
Publications Top Notes 📄
1. “Longitudinal post-radiotherapy plasma Epstein-Barr virus DNA trends inform on optimal risk stratification in endemic nasopharyngeal carcinoma”
- Authors: Neo, J., Yip, P.L., Ong, E.H.W., Lim, D.W.T., Chua, M.L.K.
- Journal: Oral Oncology, 2024, Volume 148, Article 106655.
- Summary: This study investigates plasma Epstein-Barr virus (EBV) DNA trends post-radiotherapy to refine risk stratification in nasopharyngeal carcinoma (NPC). It underscores the utility of EBV DNA as a biomarker for monitoring disease progression and treatment efficacy.
- Citations: 2
2. “Efficacy of concurrent chemoradiotherapy alone for loco-regionally advanced nasopharyngeal carcinoma: long-term follow-up analysis”
- Authors: Xu, A.-A., Miao, J.-J., Wang, L., Deng, X.-W., Zhao, C.
- Journal: Radiation Oncology, 2023, Volume 18, Issue 1, Article 63.
- Summary: This paper provides a long-term analysis of concurrent chemoradiotherapy (CCRT) as a standalone treatment for locoregionally advanced NPC. The findings highlight sustained efficacy and safety profiles, advocating for CCRT as a potential treatment standard.
- Citations: 4
3. “The m6A reader IGF2BP3 preserves NOTCH3 mRNA stability to sustain Notch3 signaling and promote tumor metastasis in nasopharyngeal carcinoma”
- Authors: Chen, B., Huang, R., Xia, T., Zhao, C., Wang, L., Miao, J.-J.
- Journal: Oncogene, 2023, Volume 42, Issue 48, Pages 3564–3574.
- Summary: This study explores the role of the m6A reader IGF2BP3 in stabilizing NOTCH3 mRNA, thereby sustaining Notch3 signaling pathways to drive metastasis in NPC. It reveals novel therapeutic targets to inhibit tumor progression.
- Citations: 8
4. “Improved accuracy of auto-segmentation of organs at risk in radiotherapy planning for nasopharyngeal carcinoma based on fully convolutional neural network deep learning”
- Authors: Peng, Y., Liu, Y., Shen, G., Qi, Z., Deng, X., Miao, J.-J.
- Journal: Oral Oncology, 2023, Volume 136, Article 106261.
- Summary: The research demonstrates advancements in radiotherapy planning through deep learning-based auto-segmentation of organs at risk (OARs), improving treatment precision and minimizing adverse effects.
- Citations: 7
5. “Adjuvant Capecitabine Following Concurrent Chemoradiotherapy in Locoregionally Advanced Nasopharyngeal Carcinoma: A Randomized Clinical Trial”
- Authors: Miao, J., Wang, L., Tan, S.H., Chua, M.L.K., Zhao, C.
- Journal: JAMA Oncology, 2022, Volume 8, Issue 12, Pages 1776–1785.
- Summary: This randomized clinical trial evaluates the addition of adjuvant capecitabine to concurrent chemoradiotherapy (CCRT) in locoregionally advanced NPC. Results show improved survival outcomes, suggesting enhanced therapeutic efficacy.
- Citations: 23
Dr. Jingjing Miao is an exemplary candidate for the Women Researcher Award. Her groundbreaking contributions to nasopharyngeal carcinoma research, leadership roles, and recognition from esteemed organizations make her deserving of this honor. Continued efforts to broaden her research scope and engage globally will further establish her as a leading figure in oncology.